ENTREPRISES FORESTIERESBusiness Directories,Company Directories

Company Name: Corporate Name:	ENTREPRISES FORESTIERES
Company Title:
Company Description:
Keywords to Search:
Company Address:	100 Rte Du Quai,SAINTE-MONIQUE-LAC-SAINT-,QC,Canada
ZIP Code: Postal Code:	G0W2T0
Telephone Number:	4183473323
Fax Number:	4183473323
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	085102
USA SIC Description:	Foresters-Consulting
Number of Employees:	20 to 49
Sales Amount:	$5 to 10 million
Credit History: Credit Report:	Very Good
Contact Person:	Jean-Claude Montminy
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
GAZ BAR JACQUES VACHON
GAUTHIER ULTRAMAR SVC
GARAGE CLAUDE PRESCOTT

Next company profile:
ECOLE BON-PASTEUR
CREATIONS PRESCOTT DESIGN
CLINIQUE BEAUTE SANTE

Company News:

One step further in targeting acute leukemia by combining antibody . . .
The results of a phase 1 clinical trial by Garcia et al showed that the combination of ipilimumab and decitabine therapy has a significant therapeutic effect and an acceptable safety profile in patients with R R MDS AML [37]
ATRA-ATO Regimen Demonstrates Superior EFS in Newly Diagnosed, High . . .
First results of the APOLLO trial: a randomized phase III study to compare ATO combined with ATRA versus standard AIDA regimen for patients with newly diagnosed, high-risk acute promyelocytic leukemia
Quizartinib Chemo Combo Shows Superiority Over Chemo Alone in Adults . . .
The combination of quizartinib and chemotherapy yielded a superior overall survival (OS) vs chemotherapy alone in adult patients with newly diagnosed FLT3-ITD –positive acute myeloid leukemia (AML), according to positive topline findings from the pivotal phase 3 QuANTUM-First trial (NCT02668653) 1
New dual-drug strategy shows promise against aggressive leukemia
Peter Mac researchers have discovered a powerful new drug combination that could offer hope to children and adults with certain subtypes of acute myeloid leukemia (AML)
New drug combination shows high remission rates in acute myeloid leukemia
A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an
Patient-reported outcomes in Philadelphia chromosome-positive acute . . .
In the Phase 3 PhALLCON trial (NCT03589326), ponatinib demonstrated superior efficacy and comparable safety profile versus imatinib in adults with newly diagnosed Philadelphia
Ibrutinib plus rituximab superior to standard treatment for some . . .
An interim analysis of a large phase 3 clinical trial found that the combination of ibrutinib plus rituximab was superior to standard treatment for patients age 70 and younger with previously untreated chronic lymphocytic leukemia (CLL)
The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN . . .
A recently-completed clinical trial in relapsed refractory AML using a combination of two newer targeted antileukemics, the BCL-2 inhibitor venetoclax (VEN) plus the FLT3 inhibitor gilteritinib (GIL), yielded highly promising results for this two-drug polypharmacy combination
Novel drug combination is safe and benefits people with acute myeloid . . .
A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an early-phase clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and 11 other sites nationwide
Precision Drug Combination Achieves 88% Response in Older Leukemia . . .
A drug combination regimen has shown high response and remission rates in patients 60 years and older who are newly diagnosed with acute myeloid leukemia (AML)